Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration

OBJECTIVE: Plasma interleukin-1 beta (IL1β) may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist (rhIL1RA) did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of rhIL1RA by baseline plasma IL1β or IL1RA concentration....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Crit Care Med
Hauptverfasser: Meyer, Nuala J., Reilly, John P., Anderson, Brian J., Palakshappa, Jessica A., Jones, Tiffanie K., Dunn, Thomas G., Shashaty, Michael G.S., Feng, Rui, Christie, Jason D., Opal, Steven M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734955/
https://ncbi.nlm.nih.gov/pubmed/28991823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000002749
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge